Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rho GDP dissociation inhibitor alpha (ARHGDIA) is a cytosolic regulator that maintains members of the Rho GTPase family—including CDC42, RAC1, and RHOA—in their inactive, GDP-bound states by preventing GDP dissociation and subsequent GTP binding. ARHGDIA extracts Rho GTPases from membranes into the cytosol, regulates their stability, protects them from degradation, and contributes to the proper distribution and recycling of the active and inactive forms. Through modulation of Rho GTPase signaling, ARHGDIA plays an essential role in cell motility, migration, cytoskeletal dynamics, and cellular homeostasis. Mutations or changes in ARHGDIA expression are associated with hereditary nephrotic syndromes and cancer cell migration and invasion.
siRNA/shRNA-mediated gene knockdown (experimental); Antibody inhibition or detection in research applications; (In principle) Small molecules or peptides inhibiting GDI activity or Rho GTPase interaction, though not clinically validated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rho GDP dissociation inhibitor alpha (ARHGDIA).